ClinicalTrials.gg
RecruitingNCT04952675Updated Jul 7, 2021

Evaluation of Pneumoconiosis High Risk Early Warning Models

An observational study in Pneumoconiosis, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-07-07.

Sponsored by Peking University Third Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2021, 4 years 11 months ago, but the record still lists the study as recruiting.
  • Started Aug 2018; still recruiting 8 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Precaution of pneumoconiosis is more important than treatment. However, the current process can't early warn the high-risk dust exposed workers until they are diagnosed with pneumoconiosis. With the feature of efficiency, impersonality and quantification, artificial intelligence is just appropriate for solving this problems. Therefore, we are aiming at adapting deep learning to develop models of pneumoconiosis intelligent detection, grade diagnosis and high risk early warning. The annotated images will be used for convolutional neural networks (CNNs) algorithm training, aiming at pneumoconiosis screening and grade diagnosis. Moreover, risk score calculated by density heat map will be used for early warning of dust-exposed workers. Then follow up of cohort will be implied to verify the validity of the risk score. By this way, the high-risk dust-exposed workers will get early intervention and better prognosis, which can obviously reduce medical burden.

Read the detailed description

Pneumoconiosis, the predominant occupational disease in China and all over the world. Chest radiography is the most accessible and affordable radiological test available for the physical examination of dust-exposed workers and mass screening for pneumoconiosis. But the diagnosis process has some disadvantages, such as strong subjectivity, inefficiency, and disability of judgement of borderline lesion, etc. Besides, precaution of pneumoconiosis is more important than treatment. However, the current process can't early warn the high-risk dust exposed workers until they are diagnosed with pneumoconiosis. With the feature of efficiency, impersonality and quantification, artificial intelligence is just appropriate for solving the aforesaid problems. Up to now, there has been rare research about adapting deep learning for pneumoconiosis grade diagnosis and high risk early warning. In our previous studies, we set up a chest radiograph database, which contains more than 100,000 digital pneumoconiosis radiography images. The result of detection-system evaluation demonstrated that the accuracy in the identification of pneumoconiosis could reach 90%, with an AUC(Area Under The Curve) of 0.965 and a sensitivity of 99%. More works need to be continued. Therefore, we are aiming at adapting deep learning to develop models of pneumoconiosis intelligent detection, grade diagnosis and high risk early warning. The annotated images will be used for convolutional neural networks (CNNs) algorithm training, aiming at pneumoconiosis screening and grade diagnosis. Moreover, risk score calculated by density heat map will be used for early warning of dust-exposed workers. Then follow up of cohort will be implied to verify the validity of the risk score. By this way, the high-risk dust-exposed workers will get early intervention and better prognosis, which can obviously reduce medical burden.

02

Conditions studied

  • Pneumoconiosis

Keywords

  • artificial intelligence
  • pneumoconiosis
  • Deep Convolutional Neural Networks
  • computer-aided diagnosis
03

In context

Lead sponsor

Peking University Third Hospital is the lead sponsor of 755 studies on the registry; 275 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

dust-exposed workers of 16 provinces of China

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. workers exposed to dust;
  2. have digital chest radiography

Exclusion criteria

Exclusion Criteria:

  1. basal pulmonary disease;
  2. dimission from dust-exposed work
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • low-risk group

    Risk Index∈\[0,0.5)

  • high-risk group

    Risk Index∈\[0.5,1)

06

What researchers measure

Primary outcomes

  1. participants diagnosed as "pneumoconiosis"

    Number of Participants diagnosed as "pneumoconiosis"

    Time frame: before December, 31,2022

  2. death

    Number of Participants who dies

    Time frame: before December, 31,2022

Secondary outcomes

  1. Forced Expiratory Volume In 1s(FEV1) in %

    Forced Expiratory Volume In 1s

    Time frame: before December, 31,2022

  2. arterial partial pressure of oxygen, PaO2

    arterial partial pressure of oxygen

    Time frame: before December, 31,2022

  3. modified Medical Research Council,mMRC

    a questionnaire used to assess symptom

    Time frame: before December, 31,2022

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2018 (actual). Primary completion is estimated for Dec 2021, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2021
First posted
Jul 7, 2021
StartActual
Aug 1, 2018
Primary completionEst.
Dec 2021
CompletionEst.
Dec 2025
Last update
Jul 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04952675
Responsible party
Sponsor
First posted
Jul 7, 2021
Start date
Aug 1, 2018
Primary completion
Dec 2021 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jul 7, 2021

Study contacts

Xiao Li, M.D.
Contact
lixiao.sy@bjmu.edu.cn
+8613051709411
Xiao Li, M.D.
principal investigator · Peking University Third Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion